Can IL-6 serve as a reliable biomarker of clinical outcome in COVID19 pneumonia?
G. Hardavella (Athens, Greece), I. Marinou (Athens, Greece), E. Keramida (Athens, Greece), E. Bellou (Athens, Greece), S. Mavrea (Athens, Greece), E. Georgakopoulou (Athens, Greece), I. Bracka (Athens, Greece), T. Daskalos (Athens, Greece), S. Mazarakis (Athens, Greece), I. Karampinis (Athens, Greece), M. Salomidou (Athens, Greece), A. Xipolitos (Athens, Greece), N. Anastasiou (Athens, Greece), D. Zorpidou (Athens, Greece), P. Demertzis (Athens, Greece), S. Karabela (Athens, Greece)
Source: International Congress 2022 – Biomarkers in COVID
Session: Biomarkers in COVID
Session type: Thematic Poster
Number: 340
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
G. Hardavella (Athens, Greece), I. Marinou (Athens, Greece), E. Keramida (Athens, Greece), E. Bellou (Athens, Greece), S. Mavrea (Athens, Greece), E. Georgakopoulou (Athens, Greece), I. Bracka (Athens, Greece), T. Daskalos (Athens, Greece), S. Mazarakis (Athens, Greece), I. Karampinis (Athens, Greece), M. Salomidou (Athens, Greece), A. Xipolitos (Athens, Greece), N. Anastasiou (Athens, Greece), D. Zorpidou (Athens, Greece), P. Demertzis (Athens, Greece), S. Karabela (Athens, Greece). Can IL-6 serve as a reliable biomarker of clinical outcome in COVID19 pneumonia?. 340
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|